?? Discover the transformative potential of Patient Experience Data (PED) in healthcare decision-making. The next session will provide clear strategies for effectively leveraging PED in different scenarios. Expert speakers will draw from their experiences and cover PED's role in organizational strategy, regulatory and HTA submissions, and advocacy initiatives. Take advantage of this opportunity and learn how to harness the full potential of PED for informed healthcare! ???Speakers: Mark Skinner (Institute for Policy Advancement Limited; ICER Board of Directors), Neil Bertelsen (HTAi/PFMD .org Board Member), Elisabeth Oehrlein, PhD, MS (Applied Px), Eda Baykal-Caglar, PhD, (The Michael J. Fox Foundation for Parkinson's Research), Nobutaka Yagi (JPPaC) ?? Explore the Global PED Navigator developed together with +300 worldwide experts: https://lnkd.in/edfUF_Rz #LastingChange #PatientEngagement #SparkingSynapses European Patients' Forum, EUPATI
PFMD .org
6 个月
Neil Bertelsen: "We have to be focused on anticipating policymakers' questions. Broad-spectrum data collection does not address specific questions. One of the challenges for PED submission is that when you submit your data and regulators have a concern or a question related to it, you only have a few weeks to react and respond."
PFMD .org
6 个月
Nobutaka Yagi: "The Patient Experience Data collection must respect the aspects of a diverse population in order to meet the special concerns and needs of the people."
Elisabeth Oehrlein, PhD, MS: "At FDA, we have reported data that Clinical outcomes assessment (COA) tools are?being used in decision making. FDA is also looking into other innovative ways to collect PED, i.e., qualitative interviews, demonstrating risk-benefit assessment to involve patients & more. It is essential that organizations know what kind of PED is available for them to use".